C9orf114 Inhibitors
Chemical inhibitors of the protein C9orf114 include a range of compounds that target various signaling pathways and kinases within cellular processes. Wortmannin and LY294002 are two such inhibitors that specifically target phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, these chemicals can lead to a decrease in AKT phosphorylation, which is a crucial step in the PI3K/AKT signaling pathway. Since AKT phosphorylation plays a significant role in a multitude of cellular functions, its inhibition can result in reduced regulatory control over the pathways that C9orf114 is associated with. Rapamycin, on the other hand, selectively inhibits the mammalian target of rapamycin (mTOR), a central component of the mTOR signaling pathway. This pathway is integral to processes like protein synthesis and cell growth. The inhibition of mTOR can disturb the activities regulated by C9orf114 if it is indeed involved in this pathway.
Continuing with the theme of kinase inhibition, PD98059 and U0126 both target MEK1/2 in the MAPK/ERK pathway, which is pivotal for cell proliferation and differentiation. By preventing the activation of ERK1/2, these inhibitors can suppress the function of C9orf114 if it plays a role in ERK-mediated signaling. Similarly, SB203580 and SP600125 inhibit p38 MAPK and JNK, respectively, both of which are kinases involved in the response to stress and inflammation. These inhibitors can decrease kinase activity necessary for C9orf114's function within these particular response pathways. Furthermore, PP2 inhibits Src family kinases, which are part of signaling cascades that can be essential for the normal function of C9orf114. Dasatinib, a broad-spectrum tyrosine kinase inhibitor, also affects Src family kinases besides Bcr-Abl, and its action can alter signaling pathways that C9orf114 may regulate. Gefitinib and Erlotinib, which selectively inhibit the epidermal growth factor receptor (EGFR) kinase, can consequently inhibit pathways in which C9orf114 is involved. Lastly, Sorafenib targets multiple kinases including RAF, VEGFR, and PDGFR, and its broad inhibitory effect can disrupt the signaling networks and thus the function of C9orf114. Each of these chemicals, by targeting different molecular components, can inhibit the functional activity of C9orf114 through their impact on the associated signaling pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases (PI3K), which are upstream regulators in pathways that could intersect with C9orf114 function. Inhibition of PI3K can lead to reduced AKT phosphorylation and activity, potentially diminishing the regulation of proteins downstream or within the same network as C9orf114. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor, and by blocking PI3K activity, it can inhibit the AKT pathway, which may be involved in the same cellular processes as C9orf114. This inhibition can lead to a reduction in the regulatory control that C9orf114 exerts on its associated pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin selectively inhibits mTOR, a key kinase in the mTOR signaling pathway. As mTOR is involved in protein synthesis and cell growth, its inhibition can disrupt processes that C9orf114 may be regulating, thereby functionally inhibiting C9orf114's role in these pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which is involved in the MAPK/ERK pathway. By inhibiting MEK, PD98059 indirectly inhibits ERK activity, which could reduce the functional activity of C9orf114 if it is involved in ERK-mediated signaling processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. By inhibiting p38 MAPK, this compound can reduce the kinase activity that may be necessary for C9orf114 to perform its function within stress response or inflammatory response pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. Inhibition of JNK can lead to disruption of JNK-mediated signaling pathways, which may include pathways where C9orf114 is a participant. Thus, inhibiting JNK can result in functional inhibition of C9orf114. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, preventing the activation of ERK1/2 in the MAPK pathway. Since this pathway is crucial for various cellular functions, U0126 can indirectly inhibit the function of C9orf114 if it is involved in the same signaling pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor. Considering that Src kinases are involved in various signaling cascades, inhibition by PP2 can lead to decreased signal transduction that might be essential for the function of C9orf114, thus indirectly inhibiting it. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, affecting Src family kinases and Bcr-Abl. By inhibiting these kinases, Dasatinib can alter signaling pathways that C9orf114 may be regulating, thereby indirectly inhibiting its function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. Since EGFR is upstream of multiple signaling pathways, its inhibition can reduce the activity of proteins involved in these pathways, including potentially C9orf114. | ||||||